REGISTRATION IS OPEN: 6th ESH Translational Research Conference LYMPHOID MALIGNANCIES

6th ESH Translational Research
Conference  LYMPHOID MALIGNANCIES 

Chairs: Michael Hallek, Georg Lenz, Laurie Sehn, Louis Staudt 

October 14-17 - E-Conference
FREE REGISTRATION

---

---

CALL FOR ABSTRACTS
for oral or poster presentations!
DEADLINE: JULY 15, 2021

---

ABOUT THE CONFERENCE

In view of continuing COVID-19 related challenges, the 6th ESH Translational Research Conference on LYMPHOID MALIGNANCIES will be held as a virtual event.

REGISTRATION IS OFFERED FREE OF CHARGE as a gesture of solidarity during these difficult times.

About the programme:
This leading-edge translational research conference will address the rapidly evolving field of lymphoid malignancies, including T- and B-cell lymphomas, and chronic lymphocytic leukaemia (CLL), from molecular pathogenesis to state-of-the-art treatment and future perspectives.

The goals of this conference are to:
– foster scientific exchange between laboratory scientists and clinicians working on lymphoid malignancies worldwide.
– foster scientific cross-fertilization between researchers and clinicians working on different diseases with partially overlapping pathogenic mechanisms such as the B cell receptor signaling, alterations of the DNA damage response, or the increasingly important dialogue of lymphoid tumour cells with their microenvironment.
– provide opportunities for leading-edge education and international networking to basic and clinical scientists, including those still in-training

A first-class selection of international speakers will guarantee the highest quality of science and a summary of the most recent developments in the biology and therapy of Lymphoid Malignancies.

Learning objectives:
Improved understanding of :
– current developments in the field of molecular pathogenesis of indolent and aggressive B-cell lymphoma including CLL
– current developments in the field of the molecular pathogenesis of T-cell lymphoma
– prognostic and predictive markers and their impact in specific clinical situations
– current treatments and future therapeutic perspectives.

SCIENTIFIC TOPICS:
– B-cell development and lymphomagenesis
– Genetics of malignant lymphomas and clonal evolution
– Epigenetics in malignant lymphomas
– Deregulated proteome and metabolome
– Single cell analyses, circulating tumor DNA, MRD
– Oncogenic signaling pathways
– Utilizing oncogenic signaling therapeutically
– Immunologic approaches in the treatment of lymphomas

To access the updated programme: click here

More information

---